Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Short-Term Debt issuances (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Short-Term Debt issuances for 7 consecutive years, with $12.2 million as the latest value for Q4 2025.

  • Quarterly Short-Term Debt issuances fell 97.77% to $12.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $233.7 million through Dec 2025, down 73.09% year-over-year, with the annual reading at $233.7 million for FY2025, 73.09% down from the prior year.
  • Short-Term Debt issuances for Q4 2025 was $12.2 million at BeOne Medicines, down from $141.5 million in the prior quarter.
  • The five-year high for Short-Term Debt issuances was $543.9 million in Q4 2024, with the low at $768000.0 in Q3 2023.
  • Average Short-Term Debt issuances over 5 years is $136.7 million, with a median of $96.2 million recorded in 2022.
  • Peak annual rise in Short-Term Debt issuances hit 820.31% in 2023, while the deepest fall reached 99.2% in 2023.
  • Over 5 years, Short-Term Debt issuances stood at $102.9 million in 2021, then soared by 45.79% to $150.0 million in 2022, then soared by 232.61% to $498.9 million in 2023, then grew by 9.01% to $543.9 million in 2024, then crashed by 97.77% to $12.2 million in 2025.
  • According to Business Quant data, Short-Term Debt issuances over the past three periods came in at $12.2 million, $141.5 million, and $80.0 million for Q4 2025, Q2 2025, and Q1 2025 respectively.